Form 8-K - Current report:
SEC Accession No. 0001628280-25-013085
Filing Date
2025-03-17
Accepted
2025-03-17 16:01:39
Documents
15
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20250317.htm   iXBRL 8-K 33869
2 EX-99.1 exhibit-991031725.htm EX-99.1 116237
6 GRAPHIC logo.gif GRAPHIC 43773
  Complete submission text file 0001628280-25-013085.txt   350799

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20250317.xsd EX-101.SCH 1795
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20250317_lab.xml EX-101.LAB 21880
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20250317_pre.xml EX-101.PRE 12520
17 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20250317_htm.xml XML 2714
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 25744301
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)